Fechtenbaum, M, Md Yusof, MY and Emery, P (2014) Certolizumab pegol in rheumatoid arthritis: Current update. Expert Opinion on Biological Therapy, 14 (6). 841 - 850. ISSN 1471-2598
Abstract
Introduction: The development of TNF-α inhibitors (TNF-is) represents a major advancement in the treatment of rheumatoid arthritis (RA). Currently, there are five agents licensed for moderate-to-severely active RA. Certolizumab pegol (CZP) is a novel PEGylated, constant fragment-free TNF-i therapy, which is the focus of this review. Areas covered: Data from Phase III randomised controlled trials in terms of clinical efficacy, radiographic progression, patient-reported outcomes and safety profile are reviewed. These include long-term data from open-label extension studies. Expert opinion: The advantages of CZP include rapid reduction of disease activity, low rates of injection-site reaction and may be safe for use in pregnancy. The long-term data strengthen the position of CZP for use either as monotherapy or preferably in combination with disease modifying anti-rheumatic drugs (DMARDs), in moderate-to-severely active RA, comparable to other TNF-is. Notably, prolonged CZP exposure is not associated with increased risk of severe infection compared to general population, contrasting with preliminary analysis of short-term data. Over the next few years, evidence will be available on the use of CZP in combination with methotrexate for remission induction in DMARD-naïve patients, biomarkers and the development and licensing of TNF-i biosimilars.
Metadata
Item Type: | Article |
---|---|
Authors/Creators: |
|
Keywords: | Anti-TNF; Biological therapy; Certolizumab; PEGylation; Rheumatoid arthritis |
Dates: |
|
Institution: | The University of Leeds |
Academic Units: | The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Institute of Rheumatology & Musculoskeletal Medicine (LIRMM) (Leeds) > Rheumatology (Leeds) |
Depositing User: | Symplectic Publications |
Date Deposited: | 24 Aug 2015 15:45 |
Last Modified: | 27 Oct 2015 01:35 |
Published Version: | http://dx.doi.org/10.1517/14712598.2014.900043 |
Status: | Published |
Publisher: | Informa Healthcare |
Identification Number: | 10.1517/14712598.2014.900043 |
Related URLs: | |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:85069 |